gip receptor vs glp 1 The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update - Nauck - 2021 - Diabetes, Obesity and Metabolism GLP-1 Receptor Agonists – Peripheral

J Clin Pathol

10.5662/wjm.v14.i1.89196 149

The analysis of the SURPASS trials of tirzepatide revealed no association between weight reduction and gastrointestinal adverse events (229)

Prescriptions of the newer anti-hyperglycemic agents continue to stagnate, even among eligible patients [19], which may be related, at least in part, to the uncertainty about the optimal clinical management of T2D

Acknowledgements This work was supported by the National Key Research and Development Program of China (2021YFF1000601), the National Natural Science Foundation of China (32172700) and the Joint Funds of the National Natural Science Foundation of China (U20A2052), and the Fundamental Research Funds for the Central Universities (grant number 2662018PY043)